ID: ALA2441842

Max Phase: Preclinical

Molecular Formula: C15H13Cl2N3O

Molecular Weight: 322.19

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)NC2

Standard InChI:  InChI=1S/C15H13Cl2N3O/c1-7-10(5-18)13(9-3-2-8(16)4-11(9)17)14-12(20-7)6-19-15(14)21/h2-4H,5-6,18H2,1H3,(H,19,21)

Standard InChI Key:  WVAJNEZWLOLVEH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 322.19

Molecular Weight (Monoisotopic): 321.0436

AlogP: 3.07

#Rotatable Bonds: 2

Polar Surface Area: 68.01

Molecular Species: BASE

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.83

CX Basic pKa: 8.79

CX LogP: 1.78

CX LogD: 0.38

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.89

Np Likeness Score: -0.75

References

1. Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG..  (2013)  Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).,  56  (18): [PMID:23964740] [10.1021/jm4008906]

Source

Source(1):

• Scientific Literature